Khachaturian ZS. Diagnosis of Alzheimer’s disease. Arch Neurol. 1985;42:1097–105.

Article  CAS  PubMed  Google Scholar 

Grasset L, Brayne C, Joly P, Jacqmin-Gadda H, Peres K, Foubert-Samier A, et al. Trends in dementia incidence: evolution over a 10-year period in France. Alzheimers Dement. 2016;12:272–80. https://doi.org/10.1016/j.jalz.2015.11.001.

Article  PubMed  Google Scholar 

Matthews FE, Stephan BC, Robinson L, Jagger C, Barnes LE, Arthur A, et al. A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. Nat Commun. 2016;7:11398. https://doi.org/10.1038/ncomms11398.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Satizabal CL, Beiser AS, Chouraki V, Chene G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med. 2016;374:523–32. https://doi.org/10.1056/NEJMoa1504327.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu YT, Fratiglioni L, Matthews FE, Lobo A, Breteler MM, Skoog I, et al. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol. 2016;15:116–24. https://doi.org/10.1016/S1474-4422(15)00092-7.

Article  CAS  PubMed  Google Scholar 

Querfurth HW, Laferla FM. Alzheimer’s disease. N Engl J Med. 2010;362:329–44.

Article  CAS  PubMed  Google Scholar 

Villemagne VL. Amyloid imaging: past, present and future perspectives. Ageing Res Rev. 2016;30:95–106. https://doi.org/10.1016/j.arr.2016.01.005.

Article  CAS  PubMed  Google Scholar 

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. https://doi.org/10.1016/j.jalz.2011.03.005.

Article  PubMed  PubMed Central  Google Scholar 

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29. https://doi.org/10.1016/S1474-4422(14)70090-0.

Article  PubMed  Google Scholar 

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44. https://doi.org/10.1212/wnl.34.7.939.

Article  CAS  PubMed  Google Scholar 

Villemagne VL, Rowe CC, Macfarlane S, Novakovic KE, Masters CL. Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer’s disease. J Clin Neurosci. 2005;12:221–30. https://doi.org/10.1016/j.jocn.2004.03.011.

Article  PubMed  Google Scholar 

Tateno A, Sakayori T, Kawashima Y, Higuchi M, Suhara T, Mizumura S, et al. Comparison of imaging biomarkers for Alzheimer’s disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. Int J Geriatr Psychiatry. 2015;30:505–13. https://doi.org/10.1002/gps.4173.

Article  PubMed  Google Scholar 

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–92. https://doi.org/10.1016/j.jalz.2011.03.003.

Article  PubMed  PubMed Central  Google Scholar 

Tian M, He X, Jin C, He X, Wu S, Zhou R, et al. Transpathology: molecular imaging-based pathology. Eur J Nucl Med Mol Imaging. 2021;48:2338–50. https://doi.org/10.1007/s00259-021-05234-1.

Article  PubMed  PubMed Central  Google Scholar 

Jacobs AH, Li H, Winkeler A, Hilker R, Knoess C, Ruger A, et al. PET-based molecular imaging in neuroscience. Eur J Nucl Med Mol Imaging. 2003;30:1051–65. https://doi.org/10.1007/s00259-003-1202-5.

Article  CAS  PubMed  Google Scholar 

Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med. 2000;41:661–81.

CAS  PubMed  Google Scholar 

Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology. 2018;91:e859–66. https://doi.org/10.1212/WNL.0000000000006075.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol. 2018;75:1062–70. https://doi.org/10.1001/jamaneurol.2018.1346.

Article  PubMed  PubMed Central  Google Scholar 

Morris E, Chalkidou A, Hammers A, Peacock J, Summers J, Keevil S. Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2016;43:374–85. https://doi.org/10.1007/s00259-015-3228-x.

Article  CAS  PubMed  Google Scholar 

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9. https://doi.org/10.1016/j.jalz.2011.03.008.

Article  PubMed  PubMed Central  Google Scholar 

Benzinger TL, Blazey T, Jack CR Jr, Koeppe RA, Su Y, Xiong C, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci U S A. 2013;110:E4502–9. https://doi.org/10.1073/pnas.1317918110.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease—the challenges ahead. Nat Rev Neurol. 2013;9:54–8. https://doi.org/10.1038/nrneurol.2012.241.

Article  CAS  PubMed  Google Scholar 

Fjell AM, Walhovd KB. New tools for the study of Alzheimer’s disease: what are biomarkers and morphometric markers teaching us? Neuroscientist. 2011;17:592–605. https://doi.org/10.1177/1073858410392586.

Article  CAS  PubMed  Google Scholar 

Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001;69:1471–84. https://doi.org/10.1016/s0024-3205(01)01232-2.

Article  CAS  PubMed  Google Scholar 

Hellwig S, Frings L, Bormann T, Vach W, Buchert R, Meyer PT. Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [(18)F]FDG PET. Eur J Nucl Med Mol Imaging. 2019;46:312–23. https://doi.org/10.1007/s00259-018-4111-3.

Article  CAS  PubMed  Google Scholar 

Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R, et al. (11)C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2014;2014:Cd010386. https://doi.org/10.1002/14651858.CD010386.pub2.

Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med: Off Publ Soc Nucl Med. 2009;50:1887–94. https://doi.org/10.2967/jnumed.109.065284.

Article  CAS  Google Scholar 

Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med: Off Publ Soc Nucl Med. 2009;50:1251–9. https://doi.org/10.2967/jnumed.109.063305.

Article  CAS  Google Scholar 

Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. The Lancet Neurol. 2008;7:129–35. https://doi.org/10.1016/s1474-4422(08)70001-2.

Article  CAS  PubMed  Google Scholar 

Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, et al. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer’s subjects. NeuroImage Clinical. 2015;9:592–8. https://doi.org/10.1016/j.nicl.2015.10.007.

Article  PubMed  PubMed Central  Google Scholar 

Juréus A, Swahn BM, Sandell J, Jeppsson F, Johnson AE, Johnström P, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem. 2010;114:784–94. https://doi.org/10.1111/j.1471-4159.2010.06812.x.

Article  CAS  PubMed  Google Scholar 

Cselényi Z, Jönhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand. J Nucl Med: Off Publ Soc Nucl Med. 2012;53:415–24. https://doi.org/10.2967/jnumed.111.094029.

Article  CAS  Google Scholar 

Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia. J Nucl Med: Off Publ Soc Nucl Med. 2013;54:880–6. https://doi.org/10.2967/jnumed.112.114785.

Article  CAS  Google Scholar 

Magnusson K, Sehlin D, Syvänen S, Svedberg MM, Philipson O, Söderberg L, et al. Specific uptake of an amyloid-β protofibril-binding antibody-tracer in AβPP transgenic mouse brain. JAD. 2013;37:29–40. https://doi.org/10.3233/jad-130029.

Article  CAS  PubMed  Google Scholar 

Fang XT, Hultqvist G, Meier SR, Antoni G, Sehlin D, Syvänen S. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain. Neuroimage. 2019;184:881–8. https://doi.org/10.1016/j.neuroimage.2018.10.011.

Article